<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944242</url>
  </required_header>
  <id_info>
    <org_study_id>40485</org_study_id>
    <nct_id>NCT00944242</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Sertraline 100 mg Tablet and ZOLOFT Following a 100 mg Dose in Healthy Subjects Under Fasting Conditions</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Torrent Pharmaceuticals Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Torrent Pharmaceuticals Limited</source>
  <brief_summary>
    <textblock>
      -  Objective:

             -  To compare the rate and extent of absorption of Torrent Pharmaceuticals Limited,
                India, sertraline and Pfizer, Inc., USA (Zoloft) sertraline, administered as a
                1X100 mg tablet, under fasted conditions.

        -  Study Design:

             -  Single-dose, open-label, randomized two-way crossover.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline Hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:

               -  Male or female, smoker or non smoker, 18 years of age and older.

               -  Capable of consent.

               -  BMI&gt;= 19.0 and &lt;30.0 kg/m2

          -  Exclusion Criteria:

        Subjects to whom any of the following applies will be excluded from the study:

          -  Clinically significant illness or surgery within 4 weeks prior to the administration
             of the study medication.

          -  Positive testing for hepatitis B, hepatitis C, or HIV at screening.

          -  ECG abnormalities or vital sign abnormalities(blood pressure).

          -  History of significant alcohol or drug abuse within one year prior to the screening
             visit.

          -  History or allergic reactions to heparin, sertraline or other related drugs.

          -  Use of an investigational drug or participation in an investigational study with in 30
             days prior to administration of the study medication.

          -  Clinically significant history of gastrointestinal pathology, liver or kidney disease,
             neurological, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or
             metabolic disease.

          -  History of seizures, suicide attempt, bipolar disorder or manic episodes.

          -  Depot injection or an implant of any drugs with in 6 months prior to administration of
             study medication.

          -  Breastfeeding subject.

          -  Positive urine pregnancy test at screening.

          -  female subject of child bearing potential having unprotected sexual intercourse with
             any non-sterile mail partner within 14 days prior to study drug administration.

        Acceptable methods of contraception:

          1. Intra-uterine contraceptive device(placed at least 4 weeks prior to study drug
             administration)

          2. Condom or diaphragm + spermicide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2009</study_first_submitted>
  <study_first_submitted_qc>July 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2009</study_first_posted>
  <last_update_submitted>July 22, 2009</last_update_submitted>
  <last_update_submitted_qc>July 22, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2009</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

